John Patton began Dance Biopharm in 2010 with a carefully selected core team. Previously, he was the co-founder of Inhale Therapeutics (now Nektar Therapeutics), where he helped lead the development and US FDA approval of the first inhaled insulin product. Prior to founding Inhale, Patton led the drug delivery group at Genentech from 1985-1990. Before that time, he was a tenured professor at the University of Georgia. Dr Patton was the founding investor in Halozyme Therapeutics, a co-founder of Incarda Therapeutics and has served as a member of the board of directors of Activaero.